Checkpoint inhibitor–associated cutaneous small vessel vasculitis

@inproceedings{Castillo2018CheckpointIC,
  title={Checkpoint inhibitor–associated cutaneous small vessel vasculitis},
  author={Brianna Castillo and Julie Diane Gibbs and Andrew S Brohl and Lucia Seminario-Vidal},
  booktitle={JAAD case reports},
  year={2018}
}
CTLA-4: cytotoxic T-lymphocyteeassociated antigen 4 GPA: granulomatosis polyangiitis PD-1: programmed cell death 1 receptor PD-L1: PD-1 ligand INTRODUCTION Under physiologic conditions, immune checkpoints provide negative signals to control T-cell activation and prevent inflammation-associated tissue destruction. Cytotoxic T-lymphocyteeassociated antigen 4 (CTLA-4), a principal negative regulator of T-cell activation, binds to CD80/CD86 on antigenpresenting cells, dampening the stimulatory… CONTINUE READING
BETA
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 1 EXCERPT

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  • The New England journal of medicine
  • 2015
VIEW 1 EXCERPT

Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…